clinical-pharmacy-2017-posters-accepted-abstracts

6 / 19

alliedacademies
Journal of Pharmacology and Therapeutic Research
Volume 1 Issue 1 Clinical Pharmacy 2017
Notes:
Page 46
December 07-09, 2017 | Rome, Italy
7th World Congress on
Clinical Pharmacy and Pharmacy Practice
Population pharmacokinetics of Amikacin in
critically ill Mexican patients with obesity
Aréchiga-Alvarado N A1, Milán-Segovia R C1, Martínez-Gutiérrez F 1,
Magaña-Aquino M2 and Romano-Moreno S1
1University of San Luis Potosí, Mexico
2Hospital Central Dr. Ignacio Morones Prieto, Mexico
Background: Amikacin is an aminoglycoside antibiotic
that is useful in the treatment of serious infections caused
by Gram-negative bacteria. The aim of this study was to
analyze the pharmacokinetic behavior of amikacin and
estimate the dosing requirements in intensive care unit
(ICU) Mexican patients with obesity using a mixed-effect
model.
Methods:The patient population comprise 50 ICU patients
of Hospital Central “Dr. Ignacio Morones Prieto” in San
Luis Potosí (México). A one-compartment intravenous
infusion model was used, and the following covariates
were tested for their influence on the clearance (CL) and
volume of distribution (Vd): age, weight, sex, height, body
mass index (BMI), ideal body weight (IBW), adjusted body
weight (ABW), serum creatinine, creatinine clearance
(CrCL), urea, blood urea nitrogen, clinical diagnosis,
mechanical ventilation and concomitant pharmacotherapy.
The nonlinear mixed-effect model (NONMEM) was used to
assess the population pharmacokinetic model of amikacin
in this patient population.
Results: The final population model accounting for
amikacin pharmacokinetics in ICU patients was: CL
(L/h) = 7.5 (CrCL/130) 0.86, Vd(L) = 20.2 (IBW/68) 2.9,
where CrCL and IBW influenced clearance and volume
of distribution amikacin, respectively. Internal and external
validations were performed to probe the stability and the
precision of the final model. Stochastic simulations were
executed to propose dosing guidelines based on the CrCL
and IBW to reach expected amikacin concentrations.
Conclusion: A population pharmacokinetic model has
been developed for ICU Mexican patients with obesity.
The predictive performance of this population model for
amikacin serum concentrations seems suitable for clinical
purposes.
Biography
Aréchiga-Alvarado is a Pharmacobiological Chemist graduated from the
Autonomous University of Zacatecas, México. After college, she has worked
in a clinical analysis laboratory, later she was a Laboratory Technician
at a university and she was in charge of a laboratory of soil and water
physicochemical analysis. She is currently graduating from the Master of
Pharmacobiological Sciences at the Autonomous University of San Luis
Potosí, México.
Aréchiga-Alvarado N A et al., J Pharmacol Ther Res 2017